---
title: "Vyome | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 31.59 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288070561.md"
datetime: "2026-05-29T12:44:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288070561.md)
  - [en](https://longbridge.com/en/news/288070561.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288070561.md)
---

# Vyome | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 31.59 K

Revenue: As of FY2026 Q1, the actual value is USD 31.59 K, beating the estimate of USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.15, beating the estimate of USD -0.18.

EBIT: As of FY2026 Q1, the actual value is USD -985.52 K.

The provided FORM 8-K filing from May 28, 2026, indicates that Vyome Holdings, Inc. announced its financial results for its first fiscal quarter ended March 31, 2026, via a press release furnished as Exhibit 99.1 to the filing. However, the actual financial results, operational metrics, cash flow, or any specific outlook/guidance are not detailed within the provided text of this FORM 8-K.

### Related Stocks

- [HIND.US](https://longbridge.com/en/quote/HIND.US.md)

## Related News & Research

- [Vyome wins China patent for besifloxacin gel in inflammatory acne](https://longbridge.com/en/news/291411688.md)
- [Vyome Therapeutics: Undervalued Buy on De-Risked VT-1953 Program and Pivotal Phase 3 Catalyst in a >$2B Orphan Market](https://longbridge.com/en/news/283873730.md)
- [Waldencast completes sale of Obagi Medical to Bridgepoint valued up to $460 million](https://longbridge.com/en/news/294416199.md)
- [Sentynl and PRG partner for Progerinin licence](https://longbridge.com/en/news/279414537.md)